Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OCEANS data add weight to Roche case for Avastin in ovarian cancer

This article was originally published in Scrip

Executive Summary

Avastin (bevacizumab) has now met the primary endpoint in three Phase III ovarian cancer trials. While Roche is currently seeking first-line approval for the IgG1 humanised monoclonal antibody against vascular endothelial growth factor (VEGF) as a treatment for ovarian cancer in Europe on the basis of the GOG-218 and ICON7 trial data (www.scripintelligence.com, 7 June, 2010 and 2 July, 2010, respectively), the results of the OCEANS trial, unveiled at the American Society of Clinical Oncology annual meeting 2011, show that Avastin can benefit patients in the second-line setting where it may be extensively used if approved for the indication.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC013188

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel